Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Alzinova announced today the successful outcome of the TO4 warrant exercise, completing the bridging financing package initiated with the rights issue earlier this year.</li><li>While a strategic partnership is still a necessary long-term funding solution for the planned phase II study of ALZ-101, we view the 94.2% exercise rate as an encouraging outcome that strengthens the company’s financial position, extends its operational runway, and provides additional flexibility in ongoing partnership discussions.</li></ul>

Alzinova announced today the successful outcome of the TO4 warrant exercise, completing the bridging financing package initiated with the rights issue earlier this year.While a strategic partnership is still a necessary long-term funding solution for the planned phase II study of ALZ-101, we view the 94.2% exercise rate as an encouraging outcome that strengthens the company’s financial position, extends its operational runway, and provides additional flexibility in ongoing partnership discussions.

Alzinova: High subscription rate in TO4 warrants

<ul><li>Redeye leaves a comment following today’s announcement of the final subscription terms for Alzinova’s TO4 warrant program.</li><li>We view the warrant exercise as an important step in further extending the company’s financial runway and reducing near-term funding uncertainty.</li></ul>

Redeye leaves a comment following today’s announcement of the final subscription terms for Alzinova’s TO4 warrant program.We view the warrant exercise as an important step in further extending the company’s financial runway and reducing near-term funding uncertainty.

Alzinova: Subscription price determined for warrants as exercise period begins

<ul><li>Redeye provides a research update following the Q1 report published by Alzinova earlier today.</li><li>The financials in the report contained no major surprises, being in line with our expectations.</li><li>Importantly, Alzinova’s scientific article based on clinical results from the Phase Ib study with ALZ-101 has now been accepted for publication.</li></ul>

Redeye provides a research update following the Q1 report published by Alzinova earlier today.The financials in the report contained no major surprises, being in line with our expectations.Importantly, Alzinova’s scientific article based on clinical results from the Phase Ib study with ALZ-101 has now been accepted for publication.

Alzinova (Q1 Review): Scientific validation and strategic optionality

<ul><li>Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test based on the company’s Aβ42CC technology.</li><li>While this represents a somewhat unexpected commercial route, we view the initiative as strategically and scientifically well-motivated.</li><li>If successful, the project could open an additional path to commercialization and strengthen the long-term value proposition of ALZ-101 through companion diagnostic opportunities.</li></ul>

Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test based on the company’s Aβ42CC technology.While this represents a somewhat unexpected commercial route, we view the initiative as strategically and scientifically well-motivated.If successful, the project could open an additional path to commercialization and strengthen the long-term value proposition of ALZ-101 through companion diagnostic opportunities.

Alzinova: Collaboration to develop innovative diagnostic test

<ul><li>Redeye leaves a comment following Alzinova’s announcement of the preliminary outcome of its SEK50.1m rights issue.</li><li>The rights issue was subscribed to 80%, in line with previously communicated commitments.</li><li>While a fully subscribed transaction would have been preferable, the outcome secures the necessary capital base and provides the company with an extended financial runway as it continues preparations for phase II and ongoing partnership discussions.</li></ul>

Redeye leaves a comment following Alzinova’s announcement of the preliminary outcome of its SEK50.1m rights issue.The rights issue was subscribed to 80%, in line with previously communicated commitments.While a fully subscribed transaction would have been preferable, the outcome secures the necessary capital base and provides the company with an extended financial runway as it continues preparations for phase II and ongoing partnership discussions.

Sweden

Alzinova AB is a Swedish clinical-stage biopharma company that develops immunotherapies for the treatment of Alzheimer's disease. Its lead product candidate is ALZ-101, a therapeutic vaccine for Alzheimer's that has completed a phase 1b study. The company is also developing ALZ-201, a monoclonal antibody that targets and neutralizes the neurotoxic forms of the peptide Aß42, known as oligomers, which are considered a primary cause of Alzheimer's disease.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alzinova (ALZ SS)

Alzinova: High subscription rate in TO4 warrants

Alzinova announced today the successful outcome of the TO4 warrant exercise, completing the bridging financing package initiated with the rights...

Redeye

Alzinova: Subscription price determined for warrants as exercise period begins

Redeye leaves a comment following today’s announcement of the final subscription terms for Alzinova’s TO4 warrant program. We view the warrant...

Redeye

Alzinova (Q1 Review): Scientific validation and strategic optionality

Redeye provides a research update following the Q1 report published by Alzinova earlier today. The financials in the report contained no major...

Redeye

Alzinova: Collaboration to develop innovative diagnostic test

Redeye comments on Alzinova’s announcement of a new research collaboration with Amsterdam UMC aimed at developing a blood-based diagnostic test...

Redeye

Alzinova: Rights issue outcome

Redeye leaves a comment following Alzinova’s announcement of the preliminary outcome of its SEK50.1m rights issue. The rights issue was subscribed...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)